Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by UBS Group

Bristol Myers Squibb (NYSE:BMY) was upgraded by UBS Group from a “neutral” rating to a “buy” rating in a report released on Wednesday, Marketbeat.com reports. The firm currently has a $65.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $46.00. UBS Group’s target price would indicate a potential upside of 16.18% from the company’s previous close.

BMY has been the subject of a number of other research reports. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research report on Wednesday, December 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. HSBC reiterated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Finally, Wells Fargo & Company upped their price objective on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $56.08.

Bristol Myers Squibb Trading Down 1.4%

Shares of Bristol Myers Squibb stock opened at $55.95 on Wednesday. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The business has a 50 day moving average price of $50.73 and a 200 day moving average price of $47.73. The company has a market capitalization of $113.89 billion, a P/E ratio of 18.90, a P/E/G ratio of 9.43 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. During the same quarter last year, the business posted $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Sell-side analysts anticipate that Bristol Myers Squibb will post 6.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sciencast Management LP bought a new position in Bristol Myers Squibb in the 1st quarter worth approximately $260,000. Signature Estate & Investment Advisors LLC grew its holdings in Bristol Myers Squibb by 4.7% in the 1st quarter. Signature Estate & Investment Advisors LLC now owns 9,134 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 410 shares in the last quarter. Great Lakes Advisors LLC grew its stake in shares of Bristol Myers Squibb by 570.1% in the first quarter. Great Lakes Advisors LLC now owns 70,859 shares of the biopharmaceutical company’s stock worth $4,322,000 after purchasing an additional 60,284 shares in the last quarter. Finally, Arete Wealth Advisors LLC grew its position in Bristol Myers Squibb by 22.2% in the 1st quarter. Arete Wealth Advisors LLC now owns 9,467 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 1,721 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY from Neutral to Buy and raised its price target to $65, which boosts near-term upside and investor sentiment. UBS upgrades Bristol-Myers Squibb (BMY)
• Positive Sentiment: Piper Sandler reiterated its Buy rating, reinforcing analyst support and demand-side confidence for the shares. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: Company-backed real-world lung cancer data was reported to add support to the nivolumab growth story, which could underpin oncology revenue momentum. Bristol-Myers Squibbs Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
• Positive Sentiment: BMY added a new immunotherapy combo bet in small-cell lung cancer (SCLC), expanding potential label and market opportunities for its immuno-oncology franchise. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Positive Sentiment: BMS quietly launched a first-in-human study of BMS-986521, indicating continued pipeline expansion and optionality beyond core drugs. Bristol-Myers Squibb Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
• Neutral Sentiment: Coverage pieces are reassessing BMY valuation as shares have run up and the profitability narrative evolves; this highlights debate between growth expectations and near-term multiples. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: An Argus/analyst report was published (general coverage), which may influence investor views but contains no single market-moving surprise. Analyst Report: Bristol-Myers Squibb Co.
• Neutral Sentiment: A broader healthcare stock roundup suggested taking advantage of select names; this is general market commentary rather than BMY-specific guidance. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Negative Sentiment: A feature questioned whether current pricing reflects renewed patent-cliff risks for Opdivo and Eliquis, which could pressure long-term revenue if generic competition accelerates. Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.